Company / PP&E (Net)
ANI Pharmaceuticals, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$62.5M
FY2025
5-year range
$43.2M / $62.5M
FY2021-FY2025
Trend
+9.9%
vs FY2024
Sector context
#57 of 193
Health Care
What the data says
At $62M, ANI Pharmaceuticals, Inc.'s pp&e (net) ranks #57 of 193 in the Health Care sector. PP&E (Net) has increased for 3 consecutive years, from $43M in FY2022 to $62M in FY2025.
Based on SEC 10-K filings.
$62M in FY2025 with a 5-year CAGR of +8.6%.
Improved from $45M to $62M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +13.0%
- 5-Year CAGR
- +8.6%
- 10-Year CAGR
- -
Sector benchmark
#57 of 193 in Health CareTop 30% of 193This company $62.5M Sector average $777.6M
▼
-92.0% below sector average
Key checks
Key Insights
- ANI Pharmaceuticals, Inc.'s pp&e (net) has grown for 3 consecutive years.
- 5-year CAGR of +8.6%, indicating consistent growth.
- In FY2025, pp&e (net) increased 9.9% year-over-year.
- Ranks #57 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $62.5M | +9.9% |
| FY2024 | $56.9M | +27.5% |
| FY2023 | $44.6M | +3.1% |
| FY2022 | $43.2M | -17.9% |
| FY2021 | $52.7M | +27.6% |
| FY2020 | $41.3M | +1.8% |
| FY2019 | $40.6M | +6.5% |
| FY2018 | $38.1M | +86.7% |
| FY2017 | $20.4M | +85.5% |
| FY2016 | $11.0M | +54.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026